Return to Today's science sparks archives

2015-04-01

Fig 1. Basic components and operation of electronic nicotine delivery systems (ENDS). When a user inhales from the ENDS device, airflow is detected by a sensor. The sensor activates a heating element that pulls the e-liquid stored in the cartridge into the vaporization chamber where it is aerosolized (ie, turned from e-liquid into a fine mist of liquid droplets, often referred to as a vapor). The aerosolized e-liquid is then inhaled by the user. In some models, activation of the sensor also powers the indicator light, which simulates the glow of burning tobacco. In manually operated models, the heating element is activated by pressing a button.

Fig 1. Basic components and operation of electronic nicotine delivery systems (ENDS). When a user inhales from the ENDS device, airflow is detected by a sensor. The sensor activates a heating element that pulls the e-liquid stored in the cartridge into the vaporization chamber where it is aerosolized (ie, turned from e-liquid into a fine mist of liquid droplets, often referred to as a vapor). The aerosolized e-liquid is then inhaled by the user. In some models, activation of the sensor also powers the indicator light, which simulates the glow of burning tobacco. In manually operated models, the heating element is activated by pressing a button.
  • Brandon TH, Goniewicz ML, Hanna NH, Hatsukami DK, Herbst RS, Hobin JA, Ostroff JS, Shields PG, Toll BA, Tyne CA, Viswanath K, Warren GW

  • J Clin Oncol. 2015 Mar 10;33(8):952-63.

2015-04-02

Graphical Abstract.

Graphical Abstract.
  • Piao J, Major T, Auyeung G, Policarpio E, Menon J, Droms L, Gutin P, Uryu K, Tchieu J, Soulet D, Tabar V

  • Cell Stem Cell. 2015 Feb 5;16(2):198-210.

2015-04-03

Fig 1. Schematic diagrams of mouse and human prostate. (A) Mouse prostate consists of four pairs of lobes arranged circumferentially around the urethra. (B) Human prostate is a compact gland, which can be divided into 3 zones: central, transition, and peripheral zones. AP, anterior prostate; DP, dorsal prostate, LP, lateral prostate; VP, ventral prostate; SV, seminal vesicle; U, urethra.

Fig 1. Schematic diagrams of mouse and human prostate. (A) Mouse prostate consists of four pairs of lobes arranged circumferentially around the urethra. (B) Human prostate is a compact gland, which can be divided into 3 zones: central, transition, and peripheral zones. AP, anterior prostate; DP, dorsal prostate, LP, lateral prostate; VP, ventral prostate; SV, seminal vesicle; U, urethra.
  • Peng YC, Joyner AL

  • Dev Biol. 2015 Apr 1;400(1):94-104.

2015-04-06

FIGURE 1— Decision tree for health counseling: Step On It!, New York City, late September–early October 2011.

FIGURE 1— Decision tree for health counseling: Step On It!, New York City, late September–early October 2011.
  • Gany F, Bari S, Gill P, Loeb R, Leng J

  • Am J Public Health. 2015 Apr;105(4):786-92

2015-04-07

Fig 2. Retroviral and lentiviral vectors' manufacturing platform.

Fig 2. Retroviral and lentiviral vectors' manufacturing platform.
  • Wang X, Rivière I

  • Cancer Gene Ther. 2015 Mar;22(2):85-94.

2015-04-08

Figure 3. Structure-Function Modeling of SMO DBP Mutants

Figure 3. Structure-Function Modeling of SMO DBP Mutants
  • Sharpe HJ, Pau G, Dijkgraaf GJ, Basset-Seguin N, Modrusan Z4, Januario T1, Tsui V5, Durham AB6, Dlugosz AA6, Haverty PM, Bourgon R, Tang JY, Sarin KY, Dirix L, Fisher DC, Rudin CM, Sofen H, Migden MR, Yauch RL, de Sauvage FJ

  • Cancer Cell. 2015 Mar 9;27(3):327-41.

2015-04-09

Fig 3. Bilateral sacroplasty. Pre- and intraoperative axial computed tomography (A, B) and variable-plane fluoroscopy (C) are used for planning and to ensure adequate filling without extrasacral cement migration. Central (D) and contralateral ala treatment can be performed as needed (E, F).

Fig 3. Bilateral sacroplasty. Pre- and intraoperative axial computed tomography (A, B) and variable-plane fluoroscopy (C) are used for planning and to ensure adequate filling without extrasacral cement migration. Central (D) and contralateral ala treatment can be performed as needed (E, F).
  • Moussazadeh N, Laufer I, Werner T, Krol G, Boland P, Bilsky MH, Lis E.

  • Neurosurgery. 2015 Apr;76(4):446-50.

2015-04-10

Fig 2. Immunofluorescent detection of T cell subpopulations in human spleen sections.

Fig 2. Immunofluorescent detection of T cell subpopulations in human spleen sections.
  • Yarilin D, Xu K, Turkekul M, Fan N, Romin Y, Fijisawa S, Barlas A, Manova-Todorova K

  • Sci Rep. 2015 Mar 31;5:9534.

2015-04-13

Fig 3. Defining VOI of the torso in two of the volunteers (A) and (B) using three cut planes (appears as lines) in sagittal view with our in-house matlab toolbox. The three lines represent three cut planes enclosing the VOI.

Fig 3. Defining VOI of the torso in two of the volunteers (A) and (B) using three cut planes (appears as lines) in sagittal view with our in-house matlab toolbox. The three lines represent three cut planes enclosing the VOI.
  • Li G, Huang H, Wei J, Li DG, Chen Q, Gaebler CP,Sullivan J, Zatcky J, Rimner A, Mechalakos J

  • Med Phys. 2015; 42:1690.

2015-04-14

Fig. 1 miR-182 is strongly induced upon B cell activation in an AID-dependent manner.

Fig. 1 miR-182 is strongly induced upon B cell activation in an AID-dependent manner.
  • Pucella JN, Yen WF, Kim MV, van der Veeken J, Socci ND, Naito Y, Li MO, Iwai N, Chaudhuri J

  • J Immunol. 2015 Mar 15;194(6):2635-42.

2015-04-15

Fig 1. Trends and Racial/Ethnic Disparities in Gluten-Sensitive Problems in the United States: Findings from the National Health and Nutrition Examination Surveys From 1988 to 2012

Fig 1. Trends and Racial/Ethnic Disparities in Gluten-Sensitive Problems in the United States: Findings from the National Health and Nutrition Examination Surveys From 1988 to 2012
  • Choung RS, Ditah IC, Nadeau AM, Rubio-Tapia A, Marietta EV, Brantner TL, Camilleri MJ, Rajkumar SV, Landgren O, Everhart JE, Murray JA

  • Am J Gastroenterol. 2015 Mar;110(3):455-61.

2015-04-16

Fig. 1. Recurrence-free survival (RFS1) by stage.

Fig. 1. Recurrence-free survival (RFS1) by stage.
  • Meisel JL, Hyman DM, Jotwani A, Zhou Q, Abu-Rustum NR, Iasonos A, Pike MC, Aghajanian C

  • Gynecol Oncol. 2015 Mar;136(3):505-11.

2015-04-17

Fig 2. ​MSI2 induction drives intestinal epithelial cell hyperproliferation and blocks differentiation.

Fig 2. ​MSI2 induction drives intestinal epithelial cell hyperproliferation and blocks differentiation.
  • Wang S, Li N, Yousefi M, Nakauka-Ddamba A, Li F, Parada K, Rao S, Minuesa G, Katz Y, Gregory BD, Kharas MG, Yu Z, Lengner CJ

  • Nat Commun. 2015 Mar 16;6:6517.

2015-04-20

Fig 1. Anti-CD19 CAR T cell (the third generation) recognizes CD19 antigen on a tumor cell via an anti-CD19 single chain Fv (scFv) binding domain. Anti-CD19 x anti-CD3 BiTE® is composed of two scFvs joined in tandem, i.e., anti-CD19 scFv and anti-CD3 scFv, recognizing CD19 on tumor cells and CD3 on T cells.

Fig 1. Anti-CD19 CAR T cell (the third generation) recognizes CD19 antigen on a tumor cell via an anti-CD19 single chain Fv (scFv) binding domain. Anti-CD19 x anti-CD3 BiTE® is composed of two scFvs joined in tandem, i.e., anti-CD19 scFv and anti-CD3 scFv, recognizing CD19 on tumor cells and CD3 on T cells.
  • Suzuki M, Curran KJ, Cheung NK

  • Pediatr Blood Cancer. 2015 Apr 1.

2015-04-21

Fig. 1. Depletion of BRCA1 and BRCA2 by shRNA in MCF-7 cells. MCF-7 cells were stably transfected with empty vector (pKLO.1) or with short hairpin RNA constructs against BRCA1 or BRCA2. The efficacy of the shRNA constructs in depleting BRCA1 (A) and BRCA2 (B) was determined by immunoblotting (actin served as loading control) and confirmed by immunofluorescence. (C) Confocal microscopic images of cell clones using immunofluorescent staining for BRCA1 and BRCA2. Wild type (empty vector) and BRCA1 or BRCA2 deficient MCF-7 cells were irradiated (10 Gy) and 4 h later, the cells were fixed and processed for BRCA1 (red) or BRCA2 (green) immunofluorescence. The nuclei were identified by DAPI staining (blue). (D) Relative survival of BRCA1- or BRCA2-deficient cells after exposure to IR. Data are the mean and SE of the mean from three independent experiments. The survival of BRCA1- and BRCA2-deficient cells relative to wild type MCF-7 at 6 Gy was compared for statistical significance. (E) Formation of Rad51 foci (green) in response to DNA damage induced by IR. Nuclei were stained with DAPI. Representative nuclei are displayed from either untreated or irradiated cells. Quantification of the percentage of foci positive cells is shown (mean and SE of the mean from three independent experiments).

Fig. 1. Depletion of BRCA1 and BRCA2 by shRNA in MCF-7 cells. MCF-7 cells were stably transfected with empty vector (pKLO.1) or with short hairpin RNA constructs against BRCA1 or BRCA2. The efficacy of the shRNA constructs in depleting BRCA1 (A) and BRCA2 (B) was determined by immunoblotting (actin served as loading control) and confirmed by immunofluorescence. (C) Confocal microscopic images of cell clones using immunofluorescent staining for BRCA1 and BRCA2. Wild type (empty vector) and BRCA1 or BRCA2 deficient MCF-7 cells were irradiated (10 Gy) and 4 h later, the cells were fixed and processed for BRCA1 (red) or BRCA2 (green) immunofluorescence. The nuclei were identified by DAPI staining (blue). (D) Relative survival of BRCA1- or BRCA2-deficient cells after exposure to IR. Data are the mean and SE of the mean from three independent experiments. The survival of BRCA1- and BRCA2-deficient cells relative to wild type MCF-7 at 6 Gy was compared for statistical significance. (E) Formation of Rad51 foci (green) in response to DNA damage induced by IR. Nuclei were stained with DAPI. Representative nuclei are displayed from either untreated or irradiated cells. Quantification of the percentage of foci positive cells is shown (mean and SE of the mean from three independent experiments).
  • Fridlich R, Annamalai D, Roy R, Bernheim G, Powell SN

  • DNA Repair (Amst). 2015 Mar 17;30:11-20.

2015-04-22

Fig 1. Histological appearance of atypical ductal hyperplasia.

Fig 1. Histological appearance of atypical ductal hyperplasia.
  • Morrow M, Schnitt SJ, Norton L

  • Nat Rev Clin Oncol. 2015 Apr;12(4):227-238.

2015-04-23

Fig 1. Identification of F. nucleatum to subspecies level by MALDI-TOF MS. (A) MALDI-TOF mass spectra of five type strains of the F. nucleatum subspecies. The upper plot shows an enlargement (6,100 to 6,500 Da) of the full mass range (3,000 to 13,000 Da), highlighting differences in peak patterns for this range. ATCC 51191, subsp. animalis; ATCC 51190, subsp. fusiforme; ATCC 49256, subsp. vincentii; ATCC 10953, subsp. polymorphum; ATCC 25586, subsp. nucleatum. (B) Cluster analysis of mass spectra of type and clinical strains of four (five) Fusobacterium nucleatum subspecies used for the amendment of the reference database. For each strain, duplicate measurements were considered.

Fig 1. Identification of F. nucleatum to subspecies level by MALDI-TOF MS. (A) MALDI-TOF mass spectra of five type strains of the F. nucleatum subspecies. The upper plot shows an enlargement (6,100 to 6,500 Da) of the full mass range (3,000 to 13,000 Da), highlighting differences in peak patterns for this range. ATCC 51191, subsp. animalis; ATCC 51190, subsp. fusiforme; ATCC 49256, subsp. vincentii; ATCC 10953, subsp. polymorphum; ATCC 25586, subsp. nucleatum. (B) Cluster analysis of mass spectra of type and clinical strains of four (five) Fusobacterium nucleatum subspecies used for the amendment of the reference database. For each strain, duplicate measurements were considered.
  • Nie S, Tian B, Wang X, Pincus DH, Welker M, Gilhuley K, Lu X, Han YW, Tang YW

  • J Clin Microbiol. 2015 Apr;53(4):1399-402.

2015-04-24

Fig 3. Depletion of mtp53 modulates PARP localization and PARP enzymatic activity. (A) Cells MDA-468 vector and MDA-468.shp53 were grown in the presence or absence of 8 μg of doxycycline for 6 d, and fractionation was carried out as described. Samples were resolved on a gradient 4–12% SDS/PAGE. Protein levels of p53, PARP1, Actin, and Fibrillarin in the fractions were determined by Western blot analysis. Actin was used to normalize the cytoplasmic and nuclear-soluble fractions, and fibrillarin was used to normalize the chromatin fraction. A total of 50 μg of protein from the cytoplasmic fraction and nuclear-soluble fractions per lane and 5 μg of the chromatin fraction per lane were resolved. ImageJ was used to quantify p53 and PARP1 change in each fraction compared with the corresponding control. (B) Confocal microscopy images of PAR proteins were obtained by using anti-PAR antibody. DAPI staining was used to determine the nucleus, and GFP was an indicator of doxycycline-mediated induction. Images are representative of three independent experiments.

Fig 3. Depletion of mtp53 modulates PARP localization and PARP enzymatic activity. (A) Cells MDA-468 vector and MDA-468.shp53 were grown in the presence or absence of 8 μg of doxycycline for 6 d, and fractionation was carried out as described. Samples were resolved on a gradient 4–12% SDS/PAGE. Protein levels of p53, PARP1, Actin, and Fibrillarin in the fractions were determined by Western blot analysis. Actin was used to normalize the cytoplasmic and nuclear-soluble fractions, and fibrillarin was used to normalize the chromatin fraction. A total of 50 μg of protein from the cytoplasmic fraction and nuclear-soluble fractions per lane and 5 μg of the chromatin fraction per lane were resolved. ImageJ was used to quantify p53 and PARP1 change in each fraction compared with the corresponding control. (B) Confocal microscopy images of PAR proteins were obtained by using anti-PAR antibody. DAPI staining was used to determine the nucleus, and GFP was an indicator of doxycycline-mediated induction. Images are representative of three independent experiments.
  • Polotskaia A, Xiao G, Reynoso K, Martin C, Qiu WG, Hendrickson RC, Bargonetti J

  • Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):E1220-9.
Open Access button

2015-04-27

Fig 1. Kaplan-Meier RFS probability curves by bladder management strategy. RFS differences were not statistically significant (log rank test p = 0.34). Cysto, cystoscopy.

Fig 1. Kaplan-Meier RFS probability curves by bladder management strategy. RFS differences were not statistically significant (log rank test p = 0.34). Cysto, cystoscopy.
  • Musser JE, O'Shaughnessy MJ, Kim PH, Herr HW

  • J Urol. 2015 Jan;193(1):48-52.

2015-04-28

Fig. 4. Prevalence of RAS mutations in all cases and in cases with metastases to lung, bone, or brain

Fig. 4. Prevalence of RAS mutations in all cases and in cases with metastases to lung, bone, or brain
  • Yaeger R, Cowell E, Chou JF, Gewirtz AN, Borsu L, Vakiani E, Solit DB, Rosen N, Capanu M, Ladanyi M, Kemeny N

  • Cancer. 2015 Apr 15;121(8):1195-203

2015-04-29

Fig 1. Nanoparticle localization reported in the literature.

Fig 1. Nanoparticle localization reported in the literature.
  • Williams RM, Shah J, Ng BD, Minton DR, Gudas LJ, Park CY, Heller DA

  • Nano Lett. 2015 Apr 8;15(4):2358-64.

2015-04-30

Fig 1. Summary of ultrasonographic findings and clinical course of study cohort.

Fig 1. Summary of ultrasonographic findings and clinical course of study cohort.
  • Peiling Yang S, Bach AM, Tuttle RM, Fish SA

  • J Clin Endocrinol Metab. 2015 Apr;100(4):1561-7.

2015-05-01

Fig 1. Top, linear model of the MEK1 gene. Exons are represented by the numbered boxes. Red boxes, regions coding for the core kinase domain (residues 55–369). Bottom, mapping of all mutations identified in this study and publically available data (cBio portal and Cosmic database).

Fig 1. Top, linear model of the MEK1 gene. Exons are represented by the numbered boxes. Red boxes, regions coding for the core kinase domain (residues 55–369). Bottom, mapping of all mutations identified in this study and publically available data (cBio portal and Cosmic database).
  • Arcila ME, Drilon A, Sylvester BE, Lovly CM, Borsu L, Reva B, Kris MG, Solit DB, Ladanyi M

  • Clin Cancer Res. 2015 Apr 15;21(8):1935-43.

2015-05-04

Fig 1. Identification of articles included for review

Fig 1. Identification of articles included for review
  • Pessin H, Fenn N, Hendriksen E, DeRosa AP, Applebaum A

  • Curr Opin Support Palliat Care. 2015 Mar;9(1):77-86.

2015-05-05

Fig 1. The difference in median costs of robotic partial nephrectomy (RPN) and open partial nephrectomy (OPN) divided into major cost groups in (left panel) all OPN and RPN cases and (right panel) OPN and RPN cases with a greater than average hospital length of stay.

Fig 1. The difference in median costs of robotic partial nephrectomy (RPN) and open partial nephrectomy (OPN) divided into major cost groups in (left panel) all OPN and RPN cases and (right panel) OPN and RPN cases with a greater than average hospital length of stay.
  • Mano R, Schulman A, Hakimi AA, Sternberg IA, Bernstein M, Bochner BH, Coleman JA, Russo P

  • Urology. 2015 Mar;85(3):596-603.

2015-05-06

Fig 1. Morphology of ALECT2 globules. A, Numerous round eosinophilic globules seen in the hepatic parenchyma. B, Prominent ALECT2 globules seen within and around a portal tract. Note the prominence of these globules around the portal vein branch (arrows). C, In the hepatic lobule the ALECT2 globules are seen within the space of Disse (arrows) and also within the hepatocytes (arrowheads). D, Prominence of amyloid globules around the central vein.

Fig 1. Morphology of ALECT2 globules. A, Numerous round eosinophilic globules seen in the hepatic parenchyma. B, Prominent ALECT2 globules seen within and around a portal tract. Note the prominence of these globules around the portal vein branch (arrows). C, In the hepatic lobule the ALECT2 globules are seen within the space of Disse (arrows) and also within the hepatocytes (arrowheads). D, Prominence of amyloid globules around the central vein.
  • Chandan VS, Shah SS, Lam-Himlin DM, Petris GD, Mereuta OM, Dogan A, Torbenson MS, Wu TT

  • Am J Surg Pathol. 2015 Apr;39(4):558-64.

2015-05-07

Fig 1. Western blot analysis of various tau species in brain lysates from Tg4510 mice of different ages.

Fig 1. Western blot analysis of various tau species in brain lysates from Tg4510 mice of different ages.
  • Song L, Lu SX, Ouyang X, Melchor J, Lee J, Terracina G, Wang X, Hyde L, Hess JF, Parker EM, Zhang L

  • Mol Neurodegener. 2015 Mar 26;10(1):14.
Open Access button

2015-05-08

Graphical Abstract

Graphical Abstract
  • Chen YH, Jones MJ, Yin Y, Crist SB, Colnaghi L, Sims RJ 3rd, Rothenberg E, Jallepalli PV, Huang TT

  • Mol Cell. 2015 Apr 16;58(2):323-38.

2015-05-11

Fig 2. Antibody-Mediated Targeting of Negative Regulators of T Cell Responses.

Fig 2. Antibody-Mediated Targeting of Negative Regulators of T Cell Responses.
  • Miller JF, Sadelain M

  • Cancer Cell. 2015 Apr 13;27(4):439-449.

2015-05-12

Fig. 1. The average size of gc clones correlates with the length of the growth phase.

Fig. 1. The average size of gc clones correlates with the length of the growth phase.
  • Legué E, Riedel E, Joyner AL

  • Development. 2015 May 1;142(9):1661-71.

2015-05-13

Fig. 2 Intertumor genetic heterogeneity in breast cancer.

Fig. 2 Intertumor genetic heterogeneity in breast cancer.
  • Ng CK, Schultheis AM, Bidard FC, Weigelt B, Reis-Filho JS

  • J Natl Cancer Inst. 2015 Feb 23;107(5)

2015-05-14

Fig.1 Topical administration of TPA to HrasG12V mice triggers papilloma development.

Fig.1 Topical administration of TPA to HrasG12V mice triggers papilloma development.
  • Chen X, Makarewicz JM, Knauf JA, Johnson LK, Fagin JA

  • Oncogene. 2014 Nov 20;33(47):5442-9.

2015-05-15

Fig. 1. EVfold_bb pipeline to de novo fold transmembrane β-barrels.

Fig. 1. EVfold_bb pipeline to de novo fold transmembrane β-barrels.
  • Hayat S, Sander C, Marks DS, Elofsson A

  • Proc Natl Acad Sci U S A. 2015 Apr 28;112(17):5413-8.
Open Access button

2015-05-18

Figure 1. Number of adverse events and percent of patients in 90-day follow-up after total gastrectomy.

Figure 1. Number of adverse events and percent of patients in 90-day follow-up after total gastrectomy.
  • Selby LV1, Vertosick EA2, Sjoberg DD2, Schattner MA3, Janjigian YY4, Brennan MF1, Coit DG1, Strong VE

  • J Am Coll Surg. 2015 May;220(5):863-871.

2015-05-19

Fig. 1. (a) Mean performance for Attention Span, Learning Efficiency, Delayed Memory, and Inaccurate Memory.

Fig. 1. (a) Mean performance for Attention Span, Learning Efficiency, Delayed Memory, and Inaccurate Memory.
  • Root JC, Ryan E, Barnett G, Andreotti C, Bolutayo K, Ahles T

  • Psychooncology. 2015 May;24(5):548-55.

2015-05-20

Graphical Abstract.

Graphical Abstract.
  • Sabari BR, Tang Z, Huang H, Yong-Gonzalez V, Molina H, Kong HE, Dai L, Shimada M, Cross JR, Zhao Y, Roeder RG, Allis CD

  • Mol Cell. 2015 Apr 16;58(2):203-15.

2015-05-21

Fig. 1. In vivo drug sensitivity assay.

Fig. 1. In vivo drug sensitivity assay.
  • Jonas O1, Landry HM1, Fuller JE2, Santini JT Jr3, Baselga J4, Tepper RI5, Cima MJ6, Langer R

  • Sci Transl Med. 2015 Apr 22;7(284):284ra57.

2015-05-22

Graphical Abstract

Graphical Abstract
  • Zheng S, Vuong BQ, Vaidyanathan B, Lin JY, Huang FT, Chaudhuri J

  • Cell. 2015 May 7;161(4):762-73.

2015-05-26

Fig 3. Therapeutic strategies to overcome immune suppression in the TME.

Fig 3. Therapeutic strategies to overcome immune suppression in the TME.
  • Joyce JA, Fearon DT

  • Science. 2015 Apr 3;348(6230):74-80.

2015-05-27

Fig 1. Aerobic training prescription and efficacy.

Fig 1. Aerobic training prescription and efficacy.
  • Glass OK, Inman BA, Broadwater G, Courneya KS, Mackey JR, Goruk S, Nelson ER, Jasper J, Field CJ, Bain JR, Muehlbauer M, Stevens RD, Hirschey MD, Jones LW

  • Br J Cancer. 2015 Mar 3;112(5):825-31.

2015-05-28

Fig 1a. Depiction of the Srsf2P95H allele.

Fig 1a. Depiction of the Srsf2P95H allele.
  • Kim E, Ilagan JO, Liang Y, Daubner GM, Lee SC, Ramakrishnan A, Li Y, Chung YR, Micol JB, Murphy ME, Cho H, Kim MK, Zebari AS, Aumann S, Park CY, Buonamici S, Smith PG, Deeg HJ, Lobry C, Aifantis I, Modis Y, Allain FH, Halene S, Bradley RK, Abdel-Wahab O

  • Cancer Cell. 2015 May 11;27(5):617-30.

2015-05-29

Fig 3. Mutation burden, clinical response, and factors contributing to mutation burden.

Fig 3. Mutation burden, clinical response, and factors contributing to mutation burden.
  • Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, Miller ML, Rekhtman N, Moreira AL, Ibrahim F, Bruggeman C, Gasmi B, Zappasodi R, Maeda Y, Sander C, Garon EB, Merghoub T, Wolchok JD, Schumacher TN, Chan TA

  • Science. 2015 Apr 3;348(6230):124-8.

2015-06-01

Fig 1. Overall Survival With Docetaxel According to Previous Paclitaxel Treatment Status.

Fig 1. Overall Survival With Docetaxel According to Previous Paclitaxel Treatment Status.
  • Sonpavde G, Pond GR, Mullane S, Qu AQ, Di Lorenzo G, Federico P, Necchi A, Rosenberg JE, Bellmunt J, Choueiri TK

  • Clin Genitourin Cancer. 2015 Jun;13(3):250-6.

2015-06-02

Fig 1. Lymphatic drainage of blank hydrogel particles.

Fig 1. Lymphatic drainage of blank hydrogel particles.
  • Mueller SN, Tian S, DeSimone JM

  • Mol Pharm. 2015 May 4;12(5):1356-65.

2015-06-03

Figure 2. Examples of Dermoscopic Images Captured by Patients Using the Mobile Dermatoscope

Figure 2. Examples of Dermoscopic Images Captured by Patients Using the Mobile Dermatoscope
  • Wu X, Oliveria SA, Yagerman S, Chen L, DeFazio J, Braun R, Marghoob AA

  • JAMA Dermatol. 2015 May 1;151(5):489-96.

2015-06-04

Fig. 1. Tumor response to voluntary aerobic exercise.

Fig. 1. Tumor response to voluntary aerobic exercise.
  • Betof AS, Lascola CD, Weitzel D, Landon C1, Scarbrough PM, Devi GR, Palmer G, Jones LW, Dewhirst MW

  • J Natl Cancer Inst. 2015 Mar 16;107(5).

2015-06-05

Fig 3. Duration of response in patients who achieved objective response by dose treatment arm. Based on data cutoff date of March 5, 2014.

Fig 3. Duration of response in patients who achieved objective response by dose treatment arm. Based on data cutoff date of March 5, 2014.
  • Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel TM, Harrison MR, Vaishampayan UN, Drabkin HA, George S, Logan TF, Margolin KA, Plimack ER, Lambert AM, Waxman IM, Hammers HJ

  • J Clin Oncol. 2015 May 1;33(13):1430-7.

2015-06-08

FIGURE 1. Comparison of SUVmax for DTC patients harboring BRAFV600E mutation versus BRAF-WT. *P = 0.019.

FIGURE 1. Comparison of SUVmax for DTC patients harboring BRAFV600E mutation versus BRAF-WT. *P = 0.019.
  • Nagarajah J, Ho AL, Tuttle RM, Weber WA, Grewal RK

  • J Nucl Med. 2015 May;56(5):662-7.

2015-06-10

Figure 1. scMHF interacts with Mph1 and Smc5 in vivo and in vitro.

Figure 1. scMHF interacts with Mph1 and Smc5 in vivo and in vitro.
  • Xue X, Choi K, Bonner JN, Szakal B, Chen YH, Papusha A, Saro D, Niu H, Ira G, Branzei D, Sung P, Zhao X

  • Genes Dev. 2015 May 15;29(10):1000-5.

2015-06-11

Fig 1. The material used for transparency tracing of melanocytic nevi is simple to obtain and of negligible cost: A translucent flexible film (3M) (support for image records) and a fine permanent ink pen for transparencies (Stabilo F, 0.4 mm width) for tracing contours; this material is showed herein for drawing the border of an intermediate melanocytic nevus located on the back of a child.

Fig 1. The material used for transparency tracing of melanocytic nevi is simple to obtain and of negligible cost: A translucent flexible film (3M) (support for image records) and a fine permanent ink pen for transparencies (Stabilo F, 0.4 mm width) for tracing contours; this material is showed herein for drawing the border of an intermediate melanocytic nevus located on the back of a child.
  • Vald S-Pineda F, Manjón-Haces J, de Castro CG, Marghoob AA, Vázquez-López F

  • Indian J Dermatol Venereol Leprol. 2015 May-Jun;81(3):283-5.

2015-06-12

Fig 1. CONSORT diagram. Patients who received none of the protocol therapy were excluded from the assessment of toxicity.

Fig 1. CONSORT diagram. Patients who received none of the protocol therapy were excluded from the assessment of toxicity.
  • Hensley ML, Miller A, O'Malley DM, Mannel RS, Behbakht K, Bakkum-Gamez JN, Michael H

  • J Clin Oncol. 2015 Apr 1;33(10):1180-5.

2015-06-15

FIGURE 1. Structure of 90Y-DOTA-AR

FIGURE 1. Structure of 90Y-DOTA-AR
  • Lohrmann C, Zhang H, Thorek DL, Desai P, Zanzonico PB, O'Donoghue J, Irwin CP, Reiner T, Grimm J, Weber WA

  • J Nucl Med. 2015 May;56(5):805-11.

2015-06-16

Fig 1. Kaplan-Meier estimates of disease-free survival for patients with locally advanced primary T4 and locally recurrent colorectal cancer.

Fig 1. Kaplan-Meier estimates of disease-free survival for patients with locally advanced primary T4 and locally recurrent colorectal cancer.
  • Terezakis S, Morikawa L, Wu A, Zhang Z, Shi W, Weiser MR, Paty PB, Guillem J, Temple L, Nash GM, Zelefsky MJ, Goodman KA

  • Ann Surg Oncol. 2015 Jul;22(7):2168-78.

2015-06-17

Graphical Abstract

Graphical Abstract
  • Voisinne G, Nixon BG, Melbinger A, Gasteiger G, Vergassola M, Altan-Bonnet G

  • Cell Rep. 2015 May;11(8):1208–19.

2015-06-18

Fig 1. Mechanisms of Stem Cell-Based Brain Repair.

Fig 1. Mechanisms of Stem Cell-Based Brain Repair.
  • Steinbeck JA, Studer L

  • Neuron. 2015 Apr 8;86(1):187-206.

2015-06-19

Fig 1. Target antigens for RIT.

Fig 1. Target antigens for RIT.
  • Larson SM, Carrasquillo JA, Cheung NK, Press OW

  • Nat Rev Cancer. 2015 May 22;15(6):347-60.

2015-06-22

Fig 1. Targeted expression of eGFP-KRASmutant transgene in zebrafish pancreas.

Fig 1. Targeted expression of eGFP-KRASmutant transgene in zebrafish pancreas.
  • Park JT, Johnson N, Liu S, Levesque M, Wang YJ, Ho H, Huso D, Maitra A, Parsons MJ, Prescott JD, Leach SD

  • Oncogene. 2015 May 21;34(21):2801-6.

2015-06-23

Fig 1. Efficacy of novel agents in relapsed, refractory mantle cell lymphoma. Single-agent overall response rates (CR + PR) are shown.

Fig 1. Efficacy of novel agents in relapsed, refractory mantle cell lymphoma. Single-agent overall response rates (CR + PR) are shown.
  • Kumar A

  • Curr Oncol Rep. 2015 Aug;17(8):460.

2015-06-24

Fig 1. Representative radiation plans for (A) a rectal cancer patient treated with 3-dimensional conformal radiation therapy and (B) an anal cancer patient treated with IMRT.

Fig 1. Representative radiation plans for (A) a rectal cancer patient treated with 3-dimensional conformal radiation therapy and (B) an anal cancer patient treated with IMRT.
  • Son CH, Law E, Oh JH, Apte AP, Yang TJ, Riedel E, Wu AJ, Deasy JO, Goodman KA

  • Int J Radiat Oncol Biol Phys. 2015 Jul 1;92(3):548-54.

2015-06-25

Fig 2. Pale areas in gastric mucosa of a patient with a germline CDH1 mutation harbouring signet ring cell focus during white light endoscopy.

Fig 2. Pale areas in gastric mucosa of a patient with a germline CDH1 mutation harbouring signet ring cell focus during white light endoscopy.
  • van der Post RS, et al.

  • J Med Genet. 2015 Jun;52(6):361-374.
Open Access button

2015-06-26

Fig 1. Graph shows ROC analysis for global T4 determination by three readers with histopathology as reference standard.

Fig 1. Graph shows ROC analysis for global T4 determination by three readers with histopathology as reference standard.
  • Gollub MJ, Lakhman Y, McGinty K, Weiser MR, Sohn M, Zheng J, Shia J

  • AJR Am J Roentgenol. 2015 Feb;204(2):W160-7.

2015-06-29

Figure 1A. In 9 patients demonstrating complete single-unit dominance from 28 days after CBT, the unit responsible for sustained donor hematopoiesis is indicated in green whereas nonengrafting units are shown in red. Only 1 patient with complete unit dominance demonstrated TL maintenance after transplantation with a mean percentage TL gain of 11.5% (indicated with the asterisk).

Figure 1A. In 9 patients demonstrating complete single-unit dominance from 28 days after CBT, the unit responsible for sustained donor hematopoiesis is indicated in green whereas nonengrafting units are shown in red. Only 1 patient with complete unit dominance demonstrated TL maintenance after transplantation with a mean percentage TL gain of 11.5% (indicated with the asterisk).
  • Ashbridge B, Zehir A, Lubin M, Barker JN, Moore MA

  • Biol Blood Marrow Transplant. 2015 Jul;21(7):1334-6.

2015-06-30

Fig 1. CRISPR/Cas-Mediated Targeting of the OCT4 Locus through Drug Selection.

Fig 1. CRISPR/Cas-Mediated Targeting of the OCT4 Locus through Drug Selection.
  • Zhu Z, Verma N, González F, Shi ZD, Huangfu D

  • Stem Cell Reports. 2015 Jun 9;4(6):1103-11.

2015-07-01

Fig 1. Effect of Sirs on Transcription of a1.

Fig 1. Effect of Sirs on Transcription of a1.
  • Wang X, Bryant G, Zhao A, Ptashne M

  • Curr Biol. 2015 May 4;25(9):1215-20.